α－2b干扰素瘤内注射治疗41例骨软组织肿瘤及转移癌  

Treatment of Bone and Soft Tissue Primary Tumor and Metastatic Cancer with Intratumoral Administration of α-2b Interferon

作　　者：李凯[1] 马育林[1] 宋金钢 姚智[1] 杨海贤 李秀英[1] 

机构地区：[1]天津市肿瘤医院骨软科,天津医科大学免疫室

出　　处：《中国肿瘤临床》1996年第12期864-869,共6页Chinese Journal of Clinical Oncology

摘　　要：１９９３年１１月～１９９５年７月，以α－２ｂ干扰素治疗骨、软组织实体瘤及转移癌４１例。其中３１例瘤内注射，１０例肌肉或皮下注射。结果显示：１）α－２ｂ干扰素对多种骨、软组织肿瘤及转移癌有较明显的局部及区域疗效，尤以恶性黑色素瘤为佳。２）瘤内注射疗效显著且肿瘤细胞及亚细胞结构有明显变化，全身用药难达此效。３）决定局部疗效的重要因素为瘤内药物浓度，而它受肿瘤体积、范围及用药途径等因素影响。４）瘤内注射后瘤组织ＣＤ４／ＣＤ８变化比较外周血ＣＤ４／ＣＤ８明显，但与某些报告不一致，其变化与疗效间亦无平行关系。提示ＣＤ４／ＣＤ８可能不适合做为衡量疗效的确切指标。From November 1993 to July 1995,41 patients with bone and soft tissue primary or metastatic tumor were treated with α-2b interferon(IFN)injection in tratumorally.Of these,31 tumors were dissolved.The results demonstrated that,1)ap parent local remission could be achieved in many bone and soft tissue tumors by α-2b IFN,especially melanoma;2)the remarkable local effect with cellular and subcellular structural changes of tumor cell were observed in cases witn intratumoral administration but not in cases given intramuscularly or subcutaneously;3)the important factor that af fected the effect was the concentration of α-2b IFN in the tumor,which depended on volume,extent of the tumor bulk,and the route of administration;4)after intratumoral injection of α-2b IFN,CD4/CD8 in the tumor tissue changed much more than in the blood,and there was no correlation between the change of CD4/CD8 value and the thera peutic efficacy.This latter event is not in accord with the literature.It is suggested that CD4/CD8 should not be rated as an indicator of the efficiency of this therapy.

关 键 词：骨肿瘤 软组织肿瘤 Α-2B干扰素 药物疗法 

分 类 号：R738.105[医药卫生—肿瘤]